SEC Form 4 · accession 0001179110-17-002974
ABBOTT LABORATORIES · ABT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph J Manning
Officer — Senior Vice President
Period of report
Feb 17, 2017
Accepted (ET)
Feb 22, 2017 · 6:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000001800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common shares without par value | Feb 21, 2017 | F | 287 | $44.69 | D | 20,292 | D | |
| Common shares without par value | Feb 21, 2017 | S | 146 | $44.981 | D | 20,146 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F1 | $44.40 | Feb 17, 2017 | A | 92,032 | A | Feb 17, 2018 | Feb 16, 2027 | Common shares | 92,032 | 92,032 | D |
Explanation of responses
- F1Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,678 on 2/17/2018, 30,677 on 2/17/2019, and 30,677 on 2/17/2020.
Remarks
The sale transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1(c).